In the UK, Bayer Pharmaceuticals, based in Leverkusen, Germany, has earned approval from the National Institute for Health and Care Excellence for its Eylea as a wet age-related macular degeneration treatment, according to a report by thepharmaletter.
Eylea, aflibercept solution for injection, is only recommended if administered within the National Health Service and National Institute for Health and Care Excellence guidelines.
More Articles on Ophthalmology:
AAO Issues Statement on Pharmaceutical Compounding Legislation
BIOLASE Earns US Patent for Laser Technologies
Valeant Acquires Bausch + Lomb for $8.7B
Eylea, aflibercept solution for injection, is only recommended if administered within the National Health Service and National Institute for Health and Care Excellence guidelines.
More Articles on Ophthalmology:
AAO Issues Statement on Pharmaceutical Compounding Legislation
BIOLASE Earns US Patent for Laser Technologies
Valeant Acquires Bausch + Lomb for $8.7B